iBio, Inc. and GE Healthcare form new global alliance

iBio, Inc. and GE Healthcare form new global alliance
--Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture --Innovative approach offers potential to reduce costs, increase manufacturing flexibility

NEWARK, Del. and CHALFONT ST GILES, England, July 26, 2012  -- iBio, Inc. (nyse mkt:IBIO), and GE Healthcare, the healthcare business of GE GE +0.15% , announced today a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's innovative plant-based vaccine manufacturing platform, iBioLaunch(TM), with GE Healthcare's world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.